Making a Kidney Cancer Drug into Tiny Particles
Author Information
Author(s): Bazaei Majid, Honarvar Bizhan, Esfandiari Nadia, Sajadian Seyed Ali, Aboosadi Zahra Arab
Primary Institution: Islamic Azad University
Hypothesis
The aim of this work is to develop pazopanib hydrochloride nanoparticles as an anti-cancer agent by the supercritical GAS method.
Conclusion
The study successfully produced pazopanib hydrochloride nanoparticles with a significant reduction in size from 37.5 μm to around 311.1 nm using optimized conditions.
Supporting Evidence
- Pressure had the most significant effect on the particle size.
- The average initial particle size of unprocessed pazopanib hydrochloride was about 37.5 ± 8.7 μm.
- The optimum process parameter values were determined to obtain the smallest particle size.
- FTIR analysis indicated that the chemical structure remained unaltered.
- DSC and XRD results confirmed the reduction in particle size.
Takeaway
Researchers found a way to make a cancer-fighting drug into tiny particles that can work better in the body.
Methodology
The Box–Behnken design was used to optimize the production of nanoparticles at varying temperatures, pressures, and solute concentrations.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website